title: Soluble epoxide hydrolase: a promising therapeutic target for cardiovascular diseases.
abstract: Epoxyeicosatrienoic acids (EETs) are cytochrome P450 (CYP450) products of arachidonic acid and EETs are endogenous lipid mediators synthesized by the vascular endothelium which perform important biological functions, including vasodilation, anti-inflammation, antimigratory, and cellular signaling regulations. However, EETs are rapidly degraded by soluble epoxide hydrolase (sEH) to the corresponding diols: dihydroxyeicosatrienoic acids (DHETs), which have little active in causing vasorelaxation. A number of studies have supported that the inhibition of sEH (sEHIs) had cardiovascular protective effects in hypertension, cardiac hypertrophy, atherosclerosis, ischemia-reperfusion injury, and ischemic stroke. Moreover, sEHIs could slow the progression of inflammation, protect end-organ damage and prevent ischemic events, also, attenuate endothelial dysfunction, suggesting that the pharmacological blockade of sEH might provide a broad and novel avenue for the treatment of many cardiovascular diseases.
authors.affiliation: Department of Cardiology, Xiang-Ya Hospital of Central South University, Changsha, PR China.
authors.forename: Guo-Hua
authors.initials: GH
authors.lastname: Ni
authors.forename: Jin-Fang
authors.initials: JF
authors.lastname: Chen
authors.forename: Xiao-Ping
authors.initials: XP
authors.lastname: Chen
authors.forename: Tian-Lun
authors.initials: TL
authors.lastname: Yang
mesh_terms: D000818:Animals; D002545:Brain Ischemia / Q000201:enzymology / Q000235:genetics; D006332:Cardiomegaly / Q000201:enzymology / Q000235:genetics; D002317:Cardiovascular Agents / Q000494:pharmacology*; D002318:Cardiovascular Diseases / Q000188:drug therapy* / Q000503:physiopathology*; D004791:Enzyme Inhibitors / Q000494:pharmacology*; D004851:Epoxide Hydrolases / Q000037:antagonists & inhibitors / Q000187:drug effects* / Q000235:genetics / Q000502:physiology*; D006801:Humans; D006973:Hypertension / Q000201:enzymology; D011110:Polymorphism, Genetic; D015427:Reperfusion Injury / Q000201:enzymology / Q000235:genetics; D012306:Risk; D020521:Stroke / Q000201:enzymology / Q000235:genetics
chemical_list: D002317:Cardiovascular Agents; D004791:Enzyme Inhibitors; D004851:Epoxide Hydrolases; C506428:EPHX2 protein, human